EraCal Therapeutics is focused on developing solutions for fighting obesity.

EraCal Therapeutics

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Skye Bioscience, Inc.

EraCal Therapeutics  | 1,964 followers on LinkedIn. Towards an efficacious and well-tolerated appetite-suppressant using our innovative in-vivo screening platform | The biotech-company EraCal Therapeutics Ltd. is a spin-off of the University of Zurich and Harvard University, and develops first-in-class drugs to treat different diseases.

Attorney at Law, LL.M., Senior Associate at VISCHER AG

Pauline Pfirter

COO and Co-founder of Eracal Therapeutics

Simon Breitler

Senior Scientist bei EraCal Therapeutics

Stephanie Niklaus

We are thrilled to see our deal with Novo Nordisk has made the finals of the European Lifestars Awards - Celebrating Life Science Leaders . Looking forward to the ceremony in London next week. https://lnkd.in/dNeDbkCx

Proud to be selected in the Top 5 of Swiss biotech scale-ups 2024. https://lnkd.in/dV2-eDzE

Congratulations to Pauline Pfirter MLaw, LL.M. who was unanimously elected to the board of directors of EraCal Therapeutics. Welcome to the team Pauline, we are looking forward to shaping the future of EraCal Therapeutics together. https://www.eracal.ch/news

EraCal Therapeutics enters into a Collaboration and License Agreement with Novo Nordisk

Metric
Company Name	EraCal Therapeutics	Skye Bioscience, Inc.
Symbol		SKYE
MSH ID	CH:ERACAL	COM:SKYEBIOSCIENCE
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	CH	US
Stage
Employee Count		11
Website	eracal.ch	skyebioscience.com
LinkedIn	eracal-therapeutics	skyebioscience
Founders

Metric
Market Cap		107.70M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ERAC

CH:ERACAL

EraCal Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue